Pharma Equity Group is listed on the Nasdaq Copenhagen Stock Exchange and places a strong emphasis on its subsidiary, Reponex Pharmaceuticals A/S (“Reponex”). Through the Company’s repositioning strategy, Reponex finds new uses for active substances that are being used in other treatments. Currently, Reponex has a pipeline of six product candidates in phase II, targeting therapeutic areas such as Peritonitis, Chronic Wounds, IBD (Crohn’s Disease and Pouchitis), and Colorectal Cancer, for which there is currently no adequate treatment. PEG's strategy is to out-license the clinical programs after the phase II trial to a pharmaceutical company capable of bringing the drugs to market.
 
PEG addresses extensive markets, encompassing millions of individuals worldwide who are suffering from the targeted diseases. The markets are forecasted to witness steady growth during the coming years, driven by factors such as rising prevalence, an aging population, heightened preference for local treatments, and increased R&D investments to develop adequate treatment options. PEG’s local treatment solutions have great potential to capture significant market shares in these expanding markets as they reach commercialization.
 
The management and board possess expertise crucial for PEG's success in clinical development as well as securing licensing agreements. In essence, PEG's repositioning and out-licensing strategy enable a capital-light and highly scalable business model, providing a shorter route to market with the same upside potential, but without the traditionally associated risks inherent in the pharmaceutical industry.
 
See an interview with Pharma Equity Group’s CEO here

About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
 
This is a press release from Analyst Group regarding the publication of an interview with Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the interview. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.